

DAFTAR PUSTAKA

1. International Diabetes Federation. IDF Diabetes Atlas. 2025.
2. World Health Organization. Diabetes [Internet]. 2024 [diakses Mei 2025]. Tersedia dari: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
3. Badan Pusat Statistik. Kota Kediri Dalam Angka 2018. Kediri: BPS; 2018. p. 1–68.
4. Dinas Kesehatan Provinsi Sumatera Barat. Laporan Dinas Kesehatan Provinsi Sumatera Barat Tahun 2022. Padang: Dinkes Sumbar; 2022.
5. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2023. Padang: DKK Padang; 2023.
6. Warsyena R, Wibisono. Nusantara Hasana Journal. Nusantara Hasana J. 2021;1(7):132–7.
7. Soelistijo S. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Glob Initiat Asthma. 2021;46.
8. Saputra S, Berawi K, Susisanti. Literature Review: Hubungan Diabetes Melitus Dengan Kejadian Gagal Ginjal Kronik. J Ilm Keperawatan (Scientific J Nursing). 2023;9(5):639–44.
9. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S1–179.
10. Johnson RJ, Feehally J, Floege JTATT. Comprehensive clinical nephrology. Sixth edit. Edinburgh: Elsevier; 2019.
11. Duta R, Ruslan P, Setiawan R, et al. Komplikasi nefropati pada DM tipe 2 di Kota Samarinda: evaluasi dosis dan profil pengobatan. Samarinda; 2023. p. 27–50. Indonesian.
12. Barendregt JJ, Nusselder WJ, Bonneux L. Global burden of disease. Lancet. 2021;350(9071).
13. Liew A, Bavanandan S, Prasad N, Wong MG, Chang JM, Eiam-Ong S, et al. Asian Pacific Society of Nephrology clinical practice guideline on diabetic kidney disease. Nephrology (Carlton) [Internet]. 2020 Oct 28;25(Suppl 2):12–45
14. Hustrini NM, Susalit E, Widjaja FF, Khumaedi AI, Dekkers OM, van Diepen M, et al. The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis. J Epidemiol Glob Health. 2024 Apr 8;14(3):740–64.
15. Perhimpunan Nefrologi Indonesia. 13th Annual Report of Indonesian Renal Registry 2020. Jakarta: PERNEFRI; 2020.
16. ES H, Decroli E, Afriwardi. Faktor risiko pasien nefropati diabetik yang Fakultas Kedokteran Universitas Andalas 33 dirawat di Bagian Penyakit

Dalam RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2018;7(2):123–9. Indonesian.

17. Pratama AAY, Chasani S, Santoso S. Korelasi Lama Diabetes Melitus Terhadap Kejadian Nefropati Diabetik : Studi Kasus Di Rumah Sakit Dokter Kariadi Semarang. J Kedokt Diponegoro. 2013;2(1).
18. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44(11):1957–72.
19. Qi C, Mao X, Zhang Z, Wu H. Classification and Differential Diagnosis of Diabetic Nephropathy. J Diabetes Res. 2017;2017:1–7.
20. Zhang A, Fang H, Chen J, He L, Chen Y. Role of VEGF-A and LRG1 in Abnormal Angiogenesis Associated With Diabetic Nephropathy. Front Physiol. 2020;11(August):1–12.
21. Holmes DIR, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6(2):209.
22. Hayman SR, Leung N, Grande JP, Garovic VD. VEGF Inhibition, Hypertension, and Renal Toxicity. Curr Oncol Rep. 2012 Aug 29;14(4):285–94.
23. Tufro A, Veron D. VEGF and Podocytes in Diabetic Nephropathy. Semin Nephrol. 2012;32(4):385–93.
24. Mahode AA. Pedoman Teknik Dasar Untuk Laboratorium Kesehatan. Journal of Chemical Information and Modeling. 2018;52:1689–1699.
25. Jiang Y, Li J, Zhang J, Chen S. Serum VEGF as a predictive marker of glycemic control and diabetic nephropathy in Chinese older adults with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Nov 22;14.
26. Aly MH, Arafat MA, Hussein OA, Elsaïd HH, Abdel-Hammed AR. Study of Angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state. Diabetes Metab Syndr Clin Res Rev. 2019 Mar;13(2):1623–7.
27. Zhang Q, Fang W, Ma L, Wang ZD, Yang YM, Lu YQ. VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes. Medicine (Baltimore). 2018 Apr;97(15):e0415.
28. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102 (5S):S1–S127.
29. Bandiara R. Podosit Dan Penyakit Ginjal Diabetes. Maranatha J Med Heal. 2011;11(1).

30. Yang KS, Lim JH, Kim TW, Kim MY, Kim Y, Chung S, et al. Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice. *PLoS One*. 2014;9(4):1–11.
31. Gosmanov AR, Wall BM, Gosmanova EO. Diagnosis and treatment of diabetic kidney disease. *Am J Med Sci*. 2014;347(5):406–13.
32. Milik A, Hryniewicz E. On translation of LD, IL and SFC given according to IEC-61131 for hardware synthesis of reconfigurable logic controller. *IFAC Proc Vol*. 2014;19(1):4477–83.
33. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, TerenceCook H, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. *J Am Soc Nephrol*. 2010;21(4):556–63.
34. Młynarska E, Buławska D, Czarnik W, Hajdys J, Majchrowicz G, Prusinowski F, et al. Novel Insights into Diabetic Kidney Disease. *Int J Mol Sci*. 2024 Sep 23;25(18):10222.
35. Young BA, Maynard C, Boyko EJ. Racial Differences in Diabetic Nephropathy, Cardiovascular Disease, and Mortality in a National Population of Veterans. *Diabetes Care*. 2003 Aug 1;26(8):2392–9.
36. Allan M, McCafferty K, Sheaff M, Yaqoob MM. Identification and management of diabetic nephropathy. *Med (United Kingdom)*. 2023;51(4):262–8.
37. Hoogeveen EK. The Epidemiology of Diabetic Kidney Disease. *Kidney Dial*. 2022 Aug 1;2(3):433–42.
38. Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Bellini MI, editor. *Biomed Res Int*. 2021 Jan 9;2021(1).
39. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. *Nat Rev Dis Prim*. 2015 Jul 30;1(1):15018.
40. Liu W, Du J, Ge X, Jiang X, Peng W, Zhao N, et al. The analysis of risk factors for diabetic kidney disease progression: a single-centre and cross-sectional experiment in Shanghai. *BMJ Open*. 2022 Jun 28;12(6):e060238.
41. Toth-Manikowski S, Atta MG. Diabetic kidney disease: Pathophysiology and therapeutic targets. *J Diabetes Res*. 2015;2015.
42. Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. *J Formos Med Assoc*. 2018;117(8):662–75.
43. Blair P, Flaumenhaft R. Platelet α -granules: Basic biology and clinical correlates. *Blood Rev*. 2009 Jul;23(4):177–89.
44. Rustiasari UJ, Roelofs JJ. The Role of Platelets in Diabetic Kidney Disease. *Int J Mol Sci*. 2022 Jul 27;23(15):8270.

45. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001 Dec 13;414(6865):813–20.
46. Nishikawa T, Edelstein D, Du XL, Yamagishi S ichi, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000 Apr;404(6779):787–90.
47. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci*. 2000 Oct 24;97(22):12222–6.
48. Ahmad I, Singh R, Pal S, Prajapati S, Sachan N, Laiq Y, et al. Exploring the Role of Glycolytic Enzymes PFKFB3 and GAPDH in the Modulation of A β and Neurodegeneration and Their Potential of Therapeutic Targets in Alzheimer's Disease. *Appl Biochem Biotechnol*. 2023 Jul 24;195(7):4673–88.
49. Verspohl EJ. Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. *Pharmacol Rev*. 2012 Apr;64(2):188–237.
50. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. *Kidney Int*. 2007 Aug;72:S49–53.
51. Chuang PY, He JC. JAK/STAT signaling in renal diseases. *Kidney Int*. 2010 Aug;78(3):231–4.
52. García-García PM. Inflammation in diabetic kidney disease. *World J Diabetes* [Internet]. 2014;5(4):431. Available from: <http://www.wjgnet.com/1948-9358/full/v5/i4/431.htm>
53. Jennette JC, Olson JL, Silva FG, D'Agati VD. *Heptinstall's Pathology of the Kidney Volume 1 and 2, 7e*. Lippincott Williams & Wilkins; 2015.
54. Akhtar M, Taha NM, Nauman A, Mujeeb IB, Al-Nabet ADMH. Diabetic Kidney Disease: Past and Present. *Adv Anat Pathol*. 2020;27(2):87–97.
55. Hall JE. *Guyton and hall textbook of medical physiology*. 13th ed. London, England: W B Saunders; 2025.
56. Shlipak MG, Inker LA, Coresh J. Serum Cystatin C for Estimation of GFR. *JAMA*. 2022 Sep 6;328(9):883.
57. Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. *Am J Kidney Dis*. 2021 Nov;78(5):736–49.
58. Stehlé T, Delanaye P. Which is the best glomerular filtration marker: Creatinine, cystatin C or both? *Eur J Clin Invest*. 2024 Oct;54(10).
59. Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A New Equation to Estimate Glomerular Filtration Rate. *Ann Intern Med*. 2009 May 5;150(9):604–12.

60. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4):S117–314.
61. Božičević S, Vučić Lovrenčić M, Smirčić Duvnjak L. Diagnostic challenges of diabetic kidney disease. *Biochem medica.* 2023 Oct 15;33(3):227–41.
62. Care D, Suppl SS. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024. *Diabetes Care.* 2024;47(January):S219–30.
63. Gupta S, Dominguez M, Golestaneh L. Diabetic Kidney Disease. *Med Clin North Am.* 2023 Jul;107(4):689–705.
64. Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, Tripepi G, et al. Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. *Nephrol Dial Transplant.* 2017;32(1):97–110.
65. Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. *Nephrology.* 2021 Jun 17;26(6):491–500.
66. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). *J Cell Mol Med.* 2005 Oct;9(4):777–94.
67. Stevens M, Oltean S. Modulation of VEGF-A alternative splicing as a novel treatment in chronic kidney disease. *Genes (Basel).* 2018;9(2).
68. Majumder S, Advani A. VEGF and the diabetic kidney: More than too much of a good thing. *J Diabetes Complications.* 2017;31(1):273–9.
69. Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. *J Cell Commun Signal.* 2016;10(4):347–54.
70. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mişu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. *Rom J Morphol Embryol.* 2018;59(2):455–67.
71. Doi K, Noiri E, Fujita T. Role of Vascular Endothelial Growth Factor in Kidney Disease. *Curr Vasc Pharmacol.* 2010;8(1):122–8.
72. Arkill KP, Qvortrup K, Starborg T, Mantell JM, Knupp C, Michel CC, et al. Resolution of the three dimensional structure of components of the glomerular filtration barrier. *BMC Nephrol.* 2014;15(1):1–13.
73. Gnudi L, Benedetti S, Woolf AS, Long DA. Vascular growth factors play critical roles in kidney glomeruli. *Clin Sci.* 2015;129(12):1225–36.
74. Neal CR. Podocytes : What's Under Yours? (Podocytes and Foot Processes and How They Change in Nephropathy). *Front Endocrinol (Lausanne).* 2015;6:1–11.

75. Abdulrahman SB, Saleh ES, Saeedi SM. Study of the reliability of serum vascular endothelial growth factor and its soluble receptor as markers of diabetic nephropathy in type 2 diabetes patients. *Int J Health Sci (Qassim)*. 2022 Jul 13;4922–34.
76. Carranza K, Veron D, Cercado A, Bautista N, Pozo W, Tufro A, et al. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A. *Nefrol (English Ed)*. 2015 Mar;35(2):131–8.
77. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. *Kidney Int*. 2010 Jun;77(11):989–99.
78. Veron D, Aggarwal PK, Li Q, Moeckel G, Kashgarian M, Tufro A. Podocyte VEGF-A Knockdown Induces Diffuse Glomerulosclerosis in Diabetic and in eNOS Knockout Mice. *Front Pharmacol*. 2022 Feb 23;12.
79. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE. Vegfa Protects the Glomerular Microvasculature in Diabetes. *Diabetes*. 2012 Nov 1;61(11):2958–66.
80. Hayrapetyan H, Tran T, Tellez-Corrales E, Madiraju C. Enzyme-Linked Immunosorbent Assay: Types and Applications. 2023: 1–17.
81. Scientific TF. Human VEGF-A ELISA Kit (BMS277-2): Instructions for Use [Internet]. <https://www.thermofisher.com/order/catalog/product/BMS277-2%0A> - Diakses 12 Juli 2025
82. Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, et al. Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders. Mischak H, editor. *PLoS One*. 2016 Jan 5;11(1):e0145375.
83. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. *Br J Cancer*. 2007 Oct 8;97(7):978–85.
84. Sjöbom U, Nilsson AK, Gyllensten H, Hellström A, Löfqvist C. A systematic review and meta-analysis of preanalytical factors and methodological differences influencing the measurement of circulating vascular endothelial growth factor. Glading AJ, editor. *PLoS One*. 2022 Jul 6;17(7):e0270232.
85. Svendsen MN, Brünner N, Christensen IJ, Ytting H, Bentsen C, Lomholt AF, et al. Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer. *Scand J Clin Lab Invest*. 2010 Nov 27;70(7):503–11.
86. Gil CL, Hooker E, Larrivée B. Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk. *Kidney Med*. 2021 Jan;3(1):105–15.

87. Tang YY, Wang DC, Wang YQ, Huang AF, Xu WD. Emerging role of hypoxia-inducible factor-1 α in inflammatory autoimmune diseases: A comprehensive review. *Front Immunol*. 2023 Jan 25;13.
88. Han Z, Li J, Yi X, Zhang T, Liao D, You J, et al. Diagnostic accuracy of interleukin-6 in multiple diseases: An umbrella review of meta-analyses. *Heliyon*. 2024 Mar;10(6):e27769.
89. Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. *Oxid Med Cell Longev*. 2020 Mar 18;2020:1–18.
90. Liu Y, Hong K, Weng W, Huang S, Zhou T. Association of vascular endothelial growth factor (VEGF) protein levels and gene polymorphism with the risk of chronic kidney disease. *Libyan J Med*. 2023 Dec 31;18(1).
91. Fabre L, Bevilaqua Rangel E. Age-related markers and predictors of diabetic kidney disease progression in type 2 diabetes patients: a retrospective cohort study. *Ther Adv Endocrinol Metab*. 2024 Jan 6;15.
92. Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis*. 5th ed. Jakarta: Sagung Seto; 2014.
93. Ravender R, Roumelioti ME, Schmidt DW, Unruh ML, Argyropoulos C. Chronic Kidney Disease in the Older Adult Patient with Diabetes. *J Clin Med*. 2024 Jan 8;13(2):348.
94. Pratama Putri CM, Mahatma G, Oktora MZ, Anggraini D. Karakteristik Penderita Diabetes Melitus Tipe 2 Dengan Komplikasi Nefropati Diabetik di RSUP Dr. M. Djamil Padang. *Sci J*. 2025 May 5;4(3):218–26.
95. de Hauteclouque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, et al. The influence of sex on renal function decline in people with Type 2 diabetes. *Diabet Med*. 2014 Sep 21;31(9):1121–8.
96. Liu J, Liu Z, Sun W, Luo L, An X, Yu D, et al. Role of sex hormones in diabetic nephropathy. *Front Endocrinol (Lausanne)*. 2023 Apr 18;14.
97. Wan KS, Hairi NN, Mustapha F, Mohd Yusoff MF, Mat Rifin H, Ismail M, et al. Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country. *Sci Rep*. 2024 Mar 25;14(1):7074.
98. Ravi H, Das S, Elumalai R, Ramanathan G. Obesity-induced diabetic kidney disease-review on pathophysiology and clinical manifestations. *J Ren Endocrinol*. 2024 Jan 1;10:e25073.
99. Buyadaa O, Salim A, Morton JI, Magliano DJ, Shaw JE. Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes. *Sci Rep*. 2021 Jul 19;11(1):14705.
100. Mok KY, Chan PF, Lai LKP, Chow KL, Chao DVK. Prevalence of diabetic nephropathy among Chinese patients with type 2 diabetes mellitus and different categories of their estimated glomerular filtration rate based on the

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in primary car. *J Diabetes Metab Disord*. 2019 Dec 15;18(2):281–8.

101. Zhang H, Yang S, Wang H, Fareeduddin Mohammed Farooqui H, Zhu W, Niu T, et al. Assessing the diagnostic utility of urinary albumin-to-creatinine ratio as a potential biomarker for diabetic peripheral neuropathy in type 2 diabetes mellitus patients. *Sci Rep*. 2024 Nov 8;14(1):27198.
102. Yang J, Liu Z. Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. *Front Endocrinol (Lausanne)*. 2022 May 25;13.
103. Chu W, Ma LL, Li BX, Li MC. Clinical significance of vascular endothelial growth factor and endothelin-1 in serum levels as novel indicators for predicting the progression of diabetic nephropathy. *Eur J Inflamm*. 2023 Jun 26;21.
104. Yang B, Zhao XH, Ma GB. Role of serum β 2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy. *World J Clin Cases*. 2022 Aug 16;10(23):8205–11.
105. Akazawa S, Sadashima E, Sera Y, Koga N. Decline in the estimated glomerular filtration rate (eGFR) following metabolic control and its relationship with baseline eGFR in type 2 diabetes with microalbuminuria or macroalbuminuria. *Diabetol Int [Internet]*. 2022 Jan 29;13(1):148–59.
106. Jaber M, Sharabati A, Nofal K, Hassan M, Hamdan Z, Nazzal Z. Decline in eGFR and mortality among type II diabetic patients: a 3-year prospective cohort study from Palestine. *BMC Nephrol [Internet]*. 2025 Feb 10;26(1):64.

